Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
Evaluating Medicare Stars for cardiovascular disease patients
Considering that cardiovascular disease (CVD) remains the leading cause of death in the United States, particularly affecting the growing population of...